Collateral for a security interest recorded Oct 19, 2022 (Orbimed Royalty & Credit Opportunities IV, LP).

Term ends Jan 21, 2035 · High confidence

Computed 20-year base term

Held by AstraZeneca AB

Filed Sep 9, 2022 as application 17/942,111 · Granted Oct 3, 2023

Base term plus 45 days of patent term adjustment (USPTO delay) · capped by a resolved terminal disclaimer

Today

20 years from filing

Term ends Jan 21, 2035

2015 2035

Clock starts
Jan 21, 2015

Term ends
Jan 21, 2035

Granted
Oct 3, 2023

base term Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Days of term adjustment

Read from the USPTO patent term adjustment record, not recalculated here.

Capped

Terminal disclaimer

Resolved from the filed document, referencing US 10,287,258, US 10,669,245, US 11,117,874, US 11,655,221, US 11,655,222, US 11,655,223, US 11,655,224, US 11,667,615, US 11,673,871, US 11,673,872, US 11,680,049, US 11,814,359, US 9,522,894, US 9,815,805.

0 of 2

Maintenance fees paid

Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.

Family applications on record here

Applications sharing this one's continuity chain whose file history this site holds. The family may have others.

This patent's term runs 45 days past its 20-year base term on prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. 0 of 2 maintenance fees are paid so far. Confidence: High. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.

Step	Input	Date after this step	Confidence
Base term, 20 years from filing	Clock starts Jan 21, 2015, when application 14/601,371, the earliest non-provisional in its chain, was filed (this one was filed Sep 9, 2022)	Jan 21, 2035	High confidence
Continuity chain	Every parent in the chain resolved	no change	High confidence
Patent term adjustment	+45 days, USPTO patent term adjustment record	Mar 7, 2035	High confidence
Terminal disclaimer cap	Disclaimer resolved from the filed document (refs US 10,287,258, US 10,669,245, US 11,117,874, US 11,655,221, US 11,655,222, US 11,655,223, US 11,655,224, US 11,667,615, US 11,673,871, US 11,673,872, US 11,680,049, US 11,814,359, US 9,522,894, US 9,815,805)	capped to Jan 21, 2035	High confidence
Patent term extension	None on file	no change	High confidence
Fee events	0 of 2 maintenance fees paid	In force	High confidence
Computed term end	The steps above, in order	Jan 21, 2035	High confidence

This family

US 9,522,894	In force Mar 2035	Mar 2035
US 9,815,805	In force Jan 2035	Jan 2035
US 10,287,258	In force Jan 2035	Jan 2035
US 10,669,245	In force Jan 2035	Jan 2035
US 11,117,874	In force Jan 2035	Jan 2035
US 11,667,615	In force Jan 2035	Jan 2035
US 11,773,069	this patent Jan 2035	Jan 2035
US 11,655,221	In force Jan 2035	Jan 2035

8 of 19 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.

Recorded	Assignor	Assignee	Conveyance
Oct 11, 2022 Reel 61379, frame 67	Lönn, Hans Roland; Pontén, John Fritiof; Aurell, Carl-johan; Po Karlsson, Staffan	AstraZeneca AB	Assignment of Assignor's Interest
Oct 11, 2022 Reel 61378, frame 992	Doyle, Kevin; Van de Poël, Amanda; Jones, Graham; Watson, David; Macritchie, Jacqueline; Palmer, Nicholas	Biofocus Dpi Ltd.	Assignment of Assignor's Interest
Oct 11, 2022 Reel 61379, frame 11	Biofocus Dpi Ltd.	AstraZeneca AB	Assignment of Assignor's Interest
Oct 11, 2022 Reel 61379, frame 27	Connolly, Stephen; Swallow, Steven	AstraZeneca UK Limited	Assignment of Assignor's Interest
Oct 11, 2022 Reel 61379, frame 55	AstraZeneca UK Limited	AstraZeneca AB	Assignment of Assignor's Interest
Oct 19, 2022 Reel 61727, frame 39	Insmed Incorporated	Orbimed Royalty & Credit Opportunities IV, LP	Second Lien Patent Security Agreement
Oct 20, 2022 Reel 61735, frame 875	Insmed Incorporated	Biopharma Credit PLC	Patent Security Agreement

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

What's changing

Jan 2035

Term ends Jan 21, 2035. Maintenance fees still fall due before then

Note

The 45 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us

Disclaimer cap

This term is capped by a terminal disclaimer resolved from the filed document, referencing US 10,287,258, US 10,669,245, US 11,117,874, US 11,655,221, US 11,655,222, US 11,655,223, US 11,655,224, US 11,667,615, US 11,673,871, US 11,673,872, US 11,680,049, US 11,814,359, US 9,522,894, US 9,815,805.

Citations

later US patents cite this one

That is top 10% of utility patents granted in 2023 in our data, the only group it is compared against. How we rank

Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.

Certain (2S)-N-[(1S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides as Dipeptidyl Peptidase 1 Inhibitors